Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8147866 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(3 years from now) | |
US9655843 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(3 years from now) | |
US9901539 | BDSI | Transmucosal drug delivery devices for use in chronic pain relief |
Dec, 2032
(9 years from now) |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 October, 2015
Treatment: Treatement of pain by transmucosal delivery of buprenorphine; Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment option...
Dosage: FILM;BUCCAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8147866 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(3 years from now) | |
US9655843 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(3 years from now) | |
US8703177 | BDSI | Abuse-resistant mucoadhesive devices for delivery of buprenorphine |
Aug, 2032
(8 years from now) | |
US9522188 | BDSI | Abuse resistant transmucosal drug delivery device |
Apr, 2035
(11 years from now) |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 06 June, 2014
Treatment: Maintenance treatment of opioid dependence; Treatment of opioid dependence
Dosage: FILM;BUCCAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9572819 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(12 years from now) | |
US10376527 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(12 years from now) | |
US9949990 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(12 years from now) | |
US10722456 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(12 years from now) | |
US10799517 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(12 years from now) | |
US9795620 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product (NP) | May 5, 2023 |
Drugs and Companies using CELECOXIB ingredient
Market Authorisation Date: 05 May, 2020
Treatment: Acute treatment of migraine with or without aura in adults
Dosage: SOLUTION;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9597288 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(3 years from now) |
Drugs and Companies using FENTANYL CITRATE ingredient
Market Authorisation Date: 16 July, 2009
Treatment: Management of breakthrough pain in patients with cancer
Dosage: FILM;BUCCAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
USRE46375 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Oct, 2026
(3 years from now) | |
USRE46365 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Jan, 2028
(4 years from now) | |
US9108975 | BDSI | Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same |
Nov, 2031
(8 years from now) | |
US10952968 | BDSI | Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives |
May, 2033
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 23, 2022 |
Drugs and Companies using NALDEMEDINE TOSYLATE ingredient
NCE-1 date: 2021-03-23
Market Authorisation Date: 23 March, 2017
Treatment: Treatment of opioid-induced constipation
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic